Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia.

Willimott S, Beck D, Ahearne MJ, Adams VC, Wagner SD.

Clin Cancer Res. 2013 Jun 15;19(12):3212-23. doi: 10.1158/1078-0432.CCR-12-2185. Epub 2013 Apr 30.


Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM.

Blood. 2009 Apr 30;113(18):4403-13. doi: 10.1182/blood-2008-08-173310. Epub 2008 Nov 13.


Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E.

Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.


Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A.

J Clin Invest. 2007 Jan;117(1):112-21.


Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.

Bates DJ, Danilov AV, Lowrey CH, Eastman A.

Mol Cancer Ther. 2013 Aug;12(8):1504-14. doi: 10.1158/1535-7163.MCT-12-1197. Epub 2013 May 30.


The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction.

Descamps G, Gomez-Bougie P, Tamburini J, Green A, Bouscary D, Maïga S, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Br J Cancer. 2012 May 8;106(10):1660-7. doi: 10.1038/bjc.2012.139. Epub 2012 Apr 17.


Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.

Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M.

Cancer. 2012 Feb 15;118(4):1023-31. doi: 10.1002/cncr.26360. Epub 2011 Jul 14.


ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.

Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL.

Biochem Pharmacol. 2013 Apr 1;85(7):927-36. doi: 10.1016/j.bcp.2013.01.011. Epub 2013 Jan 24.


Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.

Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM.

Clin Cancer Res. 2010 Aug 15;16(16):4217-25. doi: 10.1158/1078-0432.CCR-10-0777. Epub 2010 Jul 2.


γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.

Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S.

Breast Cancer Res. 2012 Jun 15;14(3):R96.


BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK, Spiekermann K.

Leukemia. 2007 Aug;21(8):1763-72. Epub 2007 Jun 7.


The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, Grigg AP, Seymour JF, Szer J, Huang DC, Roberts AW.

Leukemia. 2009 Nov;23(11):2034-41. doi: 10.1038/leu.2009.151. Epub 2009 Jul 30.


The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA.

Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30.


BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.

Potter DS, Kelly P, Denneny O, Juvin V, Stephens LR, Dive C, Morrow CJ.

Neoplasia. 2014 Feb;16(2):147-57. doi: 10.1593/neo.131376.


Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.

Song JH, Kraft AS.

Cancer Res. 2012 Jan 1;72(1):294-303. doi: 10.1158/0008-5472.CAN-11-3240. Epub 2011 Nov 11.


BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.

Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, Snowden RT, Dyer MJ, Goodall AH, Cohen GM.

Blood. 2011 Jun 30;117(26):7145-54. doi: 10.1182/blood-2011-03-344812. Epub 2011 May 11.


Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G.

Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA, Wagner G.

Cell. 2007 Jan 26;128(2):257-67.


An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.

Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, Rybicki LA, Kalaycio M, Maciejewski JP, Houghton JA, Almasan A.

Blood. 2011 Sep 29;118(13):3579-90. doi: 10.1182/blood-2011-03-340364. Epub 2011 Jul 19.

Supplemental Content

Support Center